Journal of Thyroid Disorders & Therapy
Open Access

Department of Surgery, Yamashita Thyroid Hospital, 1-8 Shimogofukumachi, Hakata-ku, Fukuoka City, Japan

Biography

Dr. Hiroyuki Yamashita is a distinguished surgeon specializing in thyroid and parathyroid disorders, serving as the Director of Surgery at Yamashita Thyroid Hospital in Fukuoka City, Japan. Under his leadership, the hospital has become a leading center for thyroid care, performing approximately 1,000 thyroid surgeries annually. In 2024, Dr. Yamashita co-authored a case report titled "Intraoperative Parathyroid Hormone Measurement Pitfalls: Parathyroid Hormone Spikes with Carboxyl-Terminal Parathyroid Hormone Fragments in Primary Hyperparathyroidism," published in Surgical Case Reports. This study examines the challenges of intraoperative parathyroid hormone (IOPTH) monitoring, highlighting potential pitfalls due to carboxyl-terminal PTH fragments, which can lead to misinterpretation during surgery. The report underscores the importance of accurate IOPTH measurement for successful surgical outcomes in primary hyperparathyroidism. In 2017, he contributed to the article "Thyroid Cytology: The Japanese System and Experience at Yamashita Thyroid Hospital," which discusses the implementation of fine-needle aspiration (FNA) cytology in Japan. The paper provides insights into the Japanese reporting system for thyroid FNA cytology and shares the hospital's experience, emphasizing the importance of accurate cytological evaluation in thyroid disease management.

Publications

• Research Article   
  Changes in Thyroid Stimulating Antibody Levels in Graves' Disease Patients: Methods to Prevent its Increase after Radioactive Iodine Therapy
  Author(s): Seigo Tachibana*, Tomohiro Ohsako, Yusuke Mori, Hisakazu Shindo, Shinya Satoh, Hiroshi Takahashi and Hiroyuki Yamashita
  
  Background: Although it is well-known that thyroid stimulating antibody levels usually increase after radioactive iodine therapy, we observed various changes in thyroid stimulating antibody levels. Methods: We divided 47 patients who underwent radioactive iodine therapy into two groups based on thyroid stimulating antibody levels three months post-therapy, as follows: the D(3M) group with increasing levels and the I(3M) group with decreasing levels of the antibody. We compared the clinical characteristics of the two groups. In addition, the 47 patients were again divided into the following two groups, and their clinical characteristics were compared: the D(6M) and I(6M) groups, which consisted of patients with decreasing and increasing thyroid stimulating antibody levels, respectively, three to six months after radioactive io.. View More»
  DOI: 10.35248/2167-7948.20.9.241

  Abstract HTML PDF

Other relevant publications from this author

• Thyroid Cytology: The Japanese System and Experience at Yamashita Thyroid Hospital

  Intraoperative parathyroid hormone measurement pitfalls: parathyroid hormone spikes with carboxyl-terminal parathyroid hormone fragments in primary hyperparathyroidism—a case report